Medical Coverage Policy | Low-Level Laser Therapy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs coverage of low-level laser therapy (photobiomodulation) for Medicare Advantage and commercial products, specifying covered indication (prevention of oral mucositis in at-risk cancer patients) and that all other indications are not covered/medically necessary. It also lists applicable procedure codes and relevant ICD-10 diagnosis code ranges for coverage.
No material clinical/coverage changes.
Coverage Summary
Policy governs coverage of low-level laser therapy (LLLT) (photobiomodulation) for Medicare Advantage and commercial products, specifying coverage for prevention (prophylactic) of oral mucositis in at-risk cancer patients and stating that all other indications are not covered/not medically necessary. Procedure codes and diagnosis code ranges applicable for coverage are listed. Coverage stance: mixed — prophylactic LLLT for oral mucositis is covered when criteria are met; other indications are not covered due to insufficient evidence.
Effective date: 2022-11-01; Last review: 2025-10-01.
Medical-Necessity Criteria
Medicare Advantage / Commercial Coverage Criteria
Covered when ALL of the following are met:
ALL of the following
- Patient is undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation
- Low-level laser therapy is used for prevention of oral mucositis (prophylactic use)
Evidence summary: The brief indicates sufficient evidence that prophylactic LLLT results in a meaningful improvement in net health outcome for prevention of oral mucositis in at-risk cancer patients, and that evidence is insufficient to determine effects for multiple musculoskeletal, neurologic, lymphedema, and wound-healing indications (evidence labels: "Sufficient evidence" — prophylactic LLLT for oral mucositis; "Insufficient evidence" — other listed indications). Recent randomized trials and systematic reviews are cited in support of the mucositis finding (see PLoS One 2014, Support Care Cancer 2007, and other systematic reviews/meta-analyses noted in the brief).
Not Covered / Not Medically Necessary Indications
Not Covered / Not Medically Necessary Indications
LLLT is not covered/considered not medically necessary for all other indications because evidence is insufficient, including but not limited to:
ANY of the following
- Carpal tunnel syndrome
- Neck pain
- Subacromial impingement
- Adhesive capsulitis
- Temporomandibular joint pain
- Low back pain
- Osteoarthritic knee pain
- Heel pain (ie, Achilles tendinopathy, plantar fasciitis)
- Rheumatoid arthritis
- Bell palsy
- Fibromyalgia
- Wound healing / chronic non-healing wounds
- Lymphedema
Rationale: LLLT is not covered for the numerous other listed indications because the evidence is judged insufficient to determine effects on health outcomes for those conditions (musculoskeletal, neurologic, lymphedema, wound healing, etc.), so these uses are considered not medically necessary under this policy.
Coding
| 0552T | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional |
| 97037 | Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non ablative) for post-operative pain reduction |
| S8948 | Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes |
| C00-D49 | Neoplasms (range) - malignancy/neoplasm diagnoses |
| K12.30-K12.39 | Stomatitis and related diagnoses (oral mucositis codes range) |
Billing and provider actions: Procedure codes (eg, 0552T, 97037, S8948) must be filed with the applicable ICD-10-CM diagnosis codes (eg, C00–D49 or K12.30–K12.39) that support prophylactic use for oral mucositis in patients undergoing cancer treatment. Claims for covered LLLT depend on correct CPT/HCPCS and ICD-10 linkage to document the qualifying diagnosis.
Provider Actions & Billing Rules
Link procedure to qualifying diagnosis
When billing the listed procedure codes, file the claim with applicable ICD-10-CM diagnosis codes that support prophylactic use for oral mucositis in patients undergoing cancer treatment (eg, malignancy/neoplasm or oral mucositis codes). Affected codes: 0552T, 97037, S8948, C00-D49, K12.30-K12.39.
Use correct CPT/HCPCS & ICD-10 linkage
The listed LLLT procedure codes are covered only when filed with the ICD-10-CM diagnosis codes indicated; verify correct CPT/HCPCS and ICD-10 linkage when submitting claims. Affected codes: 0552T, 97037, S8948, C00-D49, K12.30-K12.39. Note: benefits may vary between groups and contracts.
Member benefit determination
Member-specific benefits and eligibility are determined by the member's subscriber agreement, certificate, or employer agreement which supersede this policy. For member-specific benefit information, verify via the provider call center before delivering LLLT services.
Potential member liability for non-covered services
If services are determined to be not medically necessary or are non-covered benefits, do not charge the member unless the member was informed and agreed in writing in advance to continue treatment at their own expense.
Policy changes
BCBSRI reserves the right to review and revise this policy at any time, with or without notice; clinical practices and technology changes may prompt revisions.
Background & Definitions
Background: Low-level laser therapy (LLLT), also called photobiomodulation, uses red-beam or near-infrared lasers with wavelengths between 600–1000 nm and power between 5 and 500 mW to produce nonthermal photobiostimulative effects; the exact mechanism is uncertain but hypotheses include improved cellular repair and stimulation of immune, lymphatic, and vascular systems. When applied to the skin LLLT produces no sensation and does not burn. The evidence base supports prophylactic use of LLLT for prevention of cancer therapy–associated oral mucositis in at-risk patients, while evidence is insufficient for other indications listed in the policy.
| Term | Definition |
|---|---|
| Low-level laser therapy (LLLT) | |
| Use of red-beam or near-infrared lasers (wavelength 600–1000 nm) and power between 5 and 500 mW producing nonthermal photobiostimulative effects. | |
| Oral mucositis | |
| Inflammation of the oral mucosa manifesting as erythema or ulcerations typically 7–10 days after initiation of high-dose cancer therapy. |
Evidence Summary
Summary of evidence: Sufficient evidence supports prophylactic LLLT for prevention of oral mucositis in patients at increased risk from cancer therapies. Insufficient evidence exists for multiple other indications including a range of musculoskeletal (eg, carpal tunnel syndrome, neck pain, knee osteoarthritis), neurologic (eg, Bell palsy), lymphedema, and chronic wound-healing conditions. The brief references multiple randomized trials and systematic reviews/meta-analyses (examples cited in the policy include PLoS One 2014, Support Care Cancer 2007, and later systematic reviews and meta-analyses) supporting the mucositis conclusion.
Revision History
Policy effective
Last clinical review
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.